LA Times Publishing Launches Journal of Breakthroughs in Medicine & Science to Advance Global Scientific Research
LA Times Publishing has announced the launch of the Journal of Breakthroughs in Medicine & Science (JBMS), a peer-reviewed, open-access scientific publication designed to address longstanding challenges in academic publishing and support the faster dissemination of scientific discoveries. The multidisciplinary journal aims to connect researchers, clinicians and scientific professionals across institutions, specialties and geographical regions while promoting accessible, reliable and methodologically sound research.
The launch represents an effort to establish a modern scientific publishing platform that combines rigorous peer review with streamlined editorial and production processes. Through its international network of editors, academic researchers and peer reviewers, JBMS intends to create opportunities for collaboration and knowledge exchange across scientific disciplines, helping researchers build on existing evidence and advance the development of new approaches to medicine and healthcare.
Unlike traditional publication models that may create barriers to accessing scientific findings, JBMS operates as an open-access journal, making published research more widely available to the scientific community and the public. Its publishing framework emphasizes research quality, scientific integrity, global participation and the translation of complex scientific information into knowledge that can be understood and used by different audiences.
First Specialty Issue Focuses on Immuno-Oncology
As part of its launch, JBMS has introduced its first specialty issue, the Journal of Breakthroughs in Immuno-Oncology. The inaugural issue is dedicated to research spanning basic science, translational research and clinical investigation in cancer immunology and immunotherapy.
The specialty issue is intended to provide a multidisciplinary platform for researchers investigating the complex interactions between the immune system and cancer. Immuno-oncology has become an important area of biomedical research as scientists continue to explore how immune mechanisms can be used to recognize and attack cancer cells, improve treatment responses and address the limitations of existing therapies.
Research featured in the inaugural specialty issue highlights several priority areas within the field. These include tumor–immune interactions, mechanisms associated with treatment response and resistance, the identification and validation of biomarkers, and the development of emerging therapeutic approaches.
Tumor–immune interactions remain a central focus of cancer research because the relationship between malignant cells and the surrounding immune environment can influence how tumors develop, progress and respond to treatment. Understanding these interactions may help researchers identify new therapeutic targets and improve the design of treatments that harness the body’s immune defenses.
Treatment response and resistance represent another important area of investigation. Although immunotherapies have expanded treatment possibilities for certain cancers, not all patients respond to these approaches, and some tumors may develop mechanisms that reduce or prevent treatment effectiveness. Research into the biological processes underlying these outcomes could help scientists identify strategies for improving therapeutic responses and determining which patients are most likely to benefit from particular interventions.
Biomarker research is also essential to the advancement of precision medicine. Biomarkers can help characterize disease, assess the likelihood of treatment response and provide information about how a therapy is affecting a patient’s condition. Continued investigation into reliable biomarkers may support more individualized treatment decisions and help researchers refine clinical development strategies.
By bringing these research areas together within a dedicated specialty publication, JBMS aims to encourage the exchange of findings across basic, translational and clinical research. This approach is intended to help bridge the gap between laboratory discoveries and their potential application in patient care.
Double-Blind Peer Review Supports Scientific Integrity
Scientific credibility is a central component of the JBMS publishing model. The journal uses a double-blind peer-review process, under which the identities of authors and reviewers are concealed from one another during the review process, helping reduce potential bias in the evaluation of submitted manuscripts.
Peer review is an established component of scholarly publishing, providing an opportunity for independent experts to assess a study’s scientific rationale, methodology, analysis, interpretation and contribution to existing knowledge. Through its double-blind approach, JBMS seeks to support an impartial assessment of submitted work and maintain consistent standards for research evaluation.
Before its formal launch, the journal received 10 manuscript submissions from researchers based in different countries. These initial submissions provide an early indication of international interest in the publication, although the number of submissions alone does not establish the quality or eventual impact of the research that will be published.
JBMS has established an editorial and reviewer network intended to support the journal’s multidisciplinary scope. Its structure includes an editorial board comprising 50 members, four co-editors-in-chief and a network of 75 peer reviewers. The group includes active clinicians and academic researchers with experience in scientific investigation and healthcare.
This network is intended to provide the journal with expertise across different research disciplines, supporting the assessment of manuscripts that may involve diverse scientific methods, clinical questions and therapeutic areas. The participation of clinicians and academic researchers may also help connect research findings with practical questions relevant to healthcare delivery and future clinical investigation.
The journal has also established publishing and research-integrity guidelines consistent with principles associated with the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors (ICMJE).
These organizations provide guidance on ethical publishing practices, responsible research reporting, authorship, editorial decision-making and the management of potential conflicts of interest. Aligning its policies with their established principles reflects JBMS’s stated commitment to responsible scientific communication.
Maintaining these standards will be important as the journal expands its submissions and publication activity. Transparent editorial procedures, appropriate peer review and adherence to research-integrity principles are essential to maintaining trust among authors, reviewers, readers and the wider scientific community.
Coordinated Publishing Workflows Aim to Accelerate Research Dissemination
In addition to its peer-review framework, JBMS is introducing coordinated editorial and production workflows designed to facilitate the timely dissemination of research while preserving scientific rigor.
Scientific publishing involves several stages, including manuscript submission, editorial assessment, peer review, revision, acceptance and production. Delays at different points in this process can slow the availability of findings that may be relevant to ongoing research or clinical investigation.
JBMS aims to address this challenge by combining structured peer review with coordinated production processes. The objective is to support efficient manuscript handling without compromising the standards required to evaluate scientific work responsibly.
The journal’s approach also emphasizes the publication of methodologically sound research. This focus recognizes that scientific progress depends not only on studies reporting positive or statistically significant findings, but also on research that provides reliable methods, transparent analyses and evidence that can inform subsequent investigations.
Reproducible and well-documented research allows other scientists to evaluate published conclusions, compare findings across studies and determine whether results can be replicated under different experimental or clinical conditions. Such work can strengthen the overall evidence base and help identify limitations in existing scientific understanding.
JBMS’s stated focus on methodologically robust research is also intended to reduce unnecessary duplication of trials. When researchers can access dependable findings, including studies that clarify the limitations of particular approaches, they may be better positioned to design subsequent investigations around unresolved questions.
Reducing avoidable duplication can be particularly valuable in clinical research, where studies may require substantial resources, specialized infrastructure and participation from patients or healthy volunteers. Better access to existing evidence can help investigators refine research questions and allocate resources toward areas where additional information is needed.
However, the value of this approach will depend on the quality, completeness and accessibility of the research published through the journal, as well as the effectiveness of its editorial and review processes over time.
Publication Fee Waivers and Support for Early-Career Researchers
Improving access to scientific publishing is another major component of JBMS’s launch strategy. The journal plans to waive publication fees for eligible authors while also offering reduced rates and mentorship opportunities for early-career researchers.
Publication charges can create significant challenges for researchers whose institutions have limited funding or whose projects do not have dedicated resources for open-access publishing. These financial barriers can affect researchers’ ability to share their findings through journals that charge authors for publication.
Fee waivers and reduced publication rates are intended to help address some of these obstacles by making the publishing process more accessible to a broader range of contributors.
This approach is particularly relevant to researchers working in institutions with limited research budgets, as well as investigators at the beginning of their academic careers. Early-career scientists may have valuable findings to contribute but less experience navigating manuscript preparation, peer review, publication ethics and responses to reviewer feedback.
By offering mentorship opportunities alongside reduced fees, JBMS aims to provide additional support to researchers developing their publication skills. Mentorship can help early-career investigators better understand scholarly communication, improve the clarity of their manuscripts and respond constructively to editorial feedback.
The journal’s emphasis on international participation also reflects the importance of making scientific publishing accessible across geographical and institutional boundaries. Researchers in different regions may face unequal access to funding, editorial support and established academic networks, even when their work addresses important scientific questions.
An inclusive publishing framework can help broaden participation in scientific discussion and bring different research perspectives into the wider evidence base.
The extent to which these initiatives improve access will depend on their implementation, including the eligibility criteria for fee waivers, the availability of mentorship and the journal’s ability to sustain these programs as submissions increase.
LA Times Studios to Expand Public Engagement With Scientific Research
JBMS is also incorporating a public-engagement strategy intended to extend the reach of published research beyond traditional academic audiences.
Through an official media partnership, LA Times Studios, part of the Los Angeles Times Media Group, will support the visibility of JBMS research through digital content. Planned formats include expert interviews, multimedia discussions and accessible summaries tailored to patients and readers without specialized scientific backgrounds.
The partnership reflects an effort to connect scientific publishing with broader public communication. Although peer-reviewed research is essential to advancing scientific knowledge, technical terminology, complex statistical analyses and specialized methodologies can make academic papers difficult for non-specialists to interpret.
Accessible scientific communication can help address this challenge by explaining research questions, study methods, key findings and potential implications in language that is easier for different audiences to understand.
Expert interviews may provide additional context about the scientific reasoning behind a study, while multimedia discussions can offer opportunities to explore complex topics from different perspectives. Patient-focused summaries may also help readers understand the purpose of a research project and distinguish established evidence from questions that require further investigation.
For patients and their families, accessible information about emerging research can support a better understanding of scientific developments. For clinicians, researchers and healthcare professionals, broader dissemination may create additional opportunities to engage with findings outside their immediate specialties.
Nevertheless, communicating research to general audiences requires careful attention to accuracy and context. Findings from an early-stage study, for example, should not be presented as proof that a treatment is effective or ready for routine clinical use. Similarly, potential therapeutic applications must be distinguished from benefits demonstrated in clinical studies.
By combining a peer-reviewed publishing platform with a dedicated media partnership, JBMS and LA Times Studios aim to make scientific findings more visible while providing formats that can help audiences engage with the research.
The success of this approach will depend on preserving the distinction between scientific evidence and broader interpretation, ensuring that public-facing content accurately reflects the findings and limitations of the underlying studies.
A Multidisciplinary Model for the Future of Scientific Publishing
The launch of the Journal of Breakthroughs in Medicine & Science comes amid continued discussion across the research community about access to scientific knowledge, publication timelines, research reproducibility and the communication of discoveries to the public.
Researchers increasingly work across disciplinary boundaries, particularly in fields such as immuno-oncology, where progress can require contributions from immunology, molecular biology, oncology, genetics, biomarker development and clinical medicine.
A multidisciplinary journal can provide a shared platform for these different perspectives, helping investigators discover relevant work outside their immediate fields and identify opportunities for collaboration.
JBMS’s combination of double-blind peer review, an international editorial network, coordinated production workflows, author-support initiatives and public-facing media content represents its proposed approach to addressing several of these challenges.
Its first specialty issue establishes immuno-oncology as the initial focus of the journal’s publishing program, while the broader multidisciplinary scope provides a framework for connecting research across additional areas of medicine and science.
The journal’s long-term contribution will ultimately depend on the scientific quality of its published work, the transparency of its editorial processes, the effectiveness of its author-support programs and its ability to attract meaningful contributions from researchers around the world.
For the scientific community, the availability of another open-access publication may provide an additional route for disseminating research and encouraging collaboration. For patients and the broader public, the accompanying communication initiatives may help make complex scientific developments more understandable and accessible.
Submission Opportunities Now Open
The Journal of Breakthroughs in Medicine & Science is published by LA Times Publishing, a division of LA Times Studios. The journal has opened submissions for upcoming issues, inviting researchers to contribute work within its multidisciplinary publishing scope.
With its initial specialty issue focused on immuno-oncology, JBMS is positioning itself as a platform for research examining important questions in cancer biology, treatment response, resistance mechanisms, biomarkers and emerging therapies.
The publication’s stated mission extends beyond the distribution of academic papers. By combining established peer-review principles with efforts to reduce publication barriers, support early-career scientists and expand public engagement, JBMS aims to create a publishing environment that connects scientific discovery with wider knowledge-sharing opportunities.
Researchers interested in submitting manuscripts or learning more about the journal’s editorial scope, publishing policies and submission procedures can visit the official website at journalofbreakthrough.com.
As JBMS begins its publishing activities, its development will provide an opportunity to assess how effectively its approach supports scientific integrity, broadens participation and improves access to research across disciplines and regions.
About JBMS
Journal of Breakthroughs in Medicine & Science, LLC (JBMS) is an open-access scholarly publisher dedicated to research across the biomedical, clinical and health sciences. Its peer-reviewed journals advance understanding of human health and disease and support progress in prevention, diagnosis, treatment and patient care. JBMS places particular emphasis on work that connects biological and mechanistic insight with clinical investigation and medical application.
JBMS is committed to rigorous, transparent publishing. Each submission undergoes editorial screening, and manuscripts selected for external review go through double-blind peer review, ordinarily by at least two independent reviewers. Editorial independence is a central principle. All articles are published under the Creative Commons Attribution 4.0 (CC BY 4.0) license. Each article receives a Crossref-registered DOI with long-term preservation through Portico. JBMS also takes scientific communication beyond the journal page through interviews, podcasts, video and visual content.
About LA Times Publishing
LA Times Publishing is a division of LA Times Studios that creates original content in collaboration with expert contributors. Company leaders work with writers, researchers and industry voices to develop thoughtful, high-quality stories and editorial content for audiences across a range of platforms. Drawing on our storytelling heritage, LA Times Publishing helps contributors reach readers with engaging, credible, and carefully produced content.